Molecular evidence of IGFBP-3 dependent and independent VD3 action and its nonlinear response on IGFBP-3 induction in prostate cancer cells.

Abstract

BACKGROUND:

Clinical trials have been conducted to clarify the beneficial effects of VD3 (1α,25-dihydroxy vitamin D3, also known as calcitriol) treatment in prostate cancer. However, the molecular mechanisms underlying these effects are not fully understood. Recent studies on IGFBP-3 have indicated its intracellular functions in cell growth and apoptosis. The aim of this study was to confirm the benefits of low-dose VD3 treatment and clarify the molecular mechanisms underlying these beneficial effects in prostate cancer cells.

METHODS:

The molecular effects of simultaneous treatment of LNCaP cells and their genetically modified cell lines with low concentration of docetaxel and VD3 were biologically and biochemically analyzed. To further determine the effects of VD3 treatment on IGFBP-3 induction system, cells were temporarily treated with VD3 in combination with a transcriptional inhibitor or protein synthesis inhibitor. Bcl-2 protein and its mRNA behavior were also observed in Igfbp-3 expression-modified LNCaP cells to determine the involvement of IGFBP-3 in the suppression of Bcl-2 by VD3 treatment.

RESULTS:

Changes in IGFBP-3 expression levels in LNCaP cells indicated that it mediated the inhibition of cell growth induced by VD3 treatment. IGFBP-3 was also found to be a mediator of the enhanced cytotoxicity of prostate cancer cells to VD3 in combination with the anti-cancer drug. We further identified the distinct property of the IGFBP-3 induction system, wherein temporal VD3 stimulation-induced prolonged IGFBP-3 expression and VD3 treatment-induced increase in IGFBP-3 expression were optimized based on the protein concentration rather than the mRNA concentration. Meanwhile, Bcl-2 expression was down-regulated by VD3 treatment in an IGFBP-3-independent manner.

CONCLUSION:

These findings indicate the molecular mechanisms of IGFBP-3 induction stimulated by VD3 and IGFBP-3 independent Bcl-2 suppression by VD3 treatment in prostate cancer cells. The results could prompt a re-evaluation of VD3 usage in therapy for patients with prostate cancer.

• Authors: Ko Igarashi, Yoshihiro Yui, Kenta Watanabe, Jun Kumai, Yasuko Nishizawa, Chisato Miyaura, Masaki Inada, Satoru Sasagawa
• Journal: BMC cancer (BMC Cancer) Vol. 20 Issue 1 Pg. 802 (Aug 24 2020) ISSN: 1471-2407 [Electronic] England
• PMID: 32831047 (Publication Type: Journal Article)

Chemical References

• BCL2 protein, human
• IGFBP3 protein, human
• Insulin-Like Growth Factor Binding Protein 3
• Proto-Oncogene Proteins c-bcl-2
• Calcitriol

Topics

• Apoptosis (drug effects)
• Calcitriol (pharmacology, therapeutic use)
• Cell Line, Tumor
• Down-Regulation (drug effects)
• Drug Screening Assays, Antitumor
• Gene Expression Regulation, Neoplastic (drug effects)
• Humans
• Insulin-Like Growth Factor Binding Protein 3 (metabolism)
• Male
• Prostate (pathology)
• Prostatic Neoplasms (drug therapy, pathology)
• Proto-Oncogene Proteins c-bcl-2 (metabolism)